Account
Inquiry
XCE Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes research applications. This compound demonstrates superior efficacy in glucose control and weight management compared to selective GLP-1 receptor agonists.
The molecular mechanism of XCE Tirzepatide involves simultaneous activation of both GIP and GLP-1 receptors, with particular affinity for GIP receptors. This dual action produces enhanced hypoglycemic effects through multiple pathways: stimulating insulin secretion from pancreatic β-cells, suppressing glucagon release from α-cells, slowing gastric emptying, and promoting satiety.
For research purposes, XCE Tirzepatide is supplied as a white lyophilized powder with high purity (>98%) and proper vacuum packaging to ensure stability. The product is stable for long-term storage when kept at recommended conditions.
Key advantages of XCE Tirzepatide include its balanced receptor activation profile, extended duration of action, and superior metabolic effects compared to single-receptor agonists. These properties make it particularly valuable for investigating new approaches to metabolic disorder management.
Note: This product is intended for research use only, not for human consumption. Proper laboratory safety protocols should always be followed when handling this material.
